More to come from PARP drugs, says biotech CEO after strikin...

Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers.

BI signs KRAS deal with India's Lupin, as pharma awaits key ...

Boehringer Ingelheim has signed a deal with India’s Lupin to develop and market a potential cancer drug targeting tumours driven by the KRAS mutation.

AZ gets China nod for Tagrisso in first-line lung cancer

The promise and pitfalls of molecular testing in oncology

Great strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain that frustrate both physicians and patients.

GSK scores major trial win with potential multiple myeloma b...

GlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal DREAMM-2 trial in relapsed multiple myeloma.

AZ's immunotherapy combo misses the mark in untreated lung c...

AstraZeneca’s immunotherapy combination has missed the mark in certain patients with untreated lung cancer, failing to improve survival compared with standard chemotherapy in a phase 3 tria